Both knockdown of NKCC1 and inhibition with bumetanide significantly reduces GBM cell migration in vitro and in vivo, and overexpression of the transporter markedly increases GBM cell invasion (Haas and Sontheimer, 2010; Garzon-Muvdi et al., 2012; Schiapparelli et al., 2017). This evidence concerns the gene SLC12A2 and glioblastoma.